Bayer reveals data behind asundexian's stroke win Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial

#Bayer #asundexian #stroke #oralFactorXIainhibitor #FactorXIainhibitor #ischaemicstroke #OCEANICSTROKEstudy #antiplatelettherapy #InternationalStrokeConference #phase3trial #secondarystrokeprevention #anticlottingtherapies #OCEANICSTROKE #acutecoronarysyndromes #preventionofstroke
zurl.co/Mhc1J

Stroke data breathes life back into Bayer's asundexian Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.

Prospects for #Bayer's oral #FactorXIainhibitor asundexian were looking speculative when it failed a phase 3 trial in atrial fibrillation (AF), but new data in secondary #strokeprevention could get the programme back on track.